Therapeutics And Diagnostics For Women's Disorders
April 02, 2009
Wellesley, Mass—According to a new technical market research report, THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS (BIO043D) from BCC Research (www.bccresearch.com), the U.S. market for therapeutics and diagnostics for women’s disorders was worth almost $30.0 billion in 2008. This is expected to reach $50.0 billion in 2013, for a compound annual growth rate (CAGR) of 10.9%.
The market is broken down into segments for autoimmune diseases; cancer; gynecological diseases and infections; kidney and urological diseases and infections; reproductive-related therapies and diagnostics; and rheumatoid arthritis and osteoporosis. Of these, therapeutics and diagnostics for rheumatoid arthritis and osteoporosis have the largest share of the market, generating nearly $11.0 billion in 2008. This is expected to increase to $18.2 billion in 2013, for a CAGR of 11.5%.
Reproductive-related therapies and diagnostics currently have the second largest share of the market, worth $5.9 billion in 2008. This is expected to increase at a CAGR of 5.0% to reach $7.5 billion in 2013.
The application segment for cancer is the third largest market segment, generating $5.8 billion in revenues in 2008. This should increase to $11.3 billion in 2013, for a CAGR of 14.6%.
SUMMARY FIGURE
U.S. MARKET FORECAST FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS BY SEGMENT, 2006-2013
($ MILLIONS)
To Contact us, click here 
Source: BCC Research
The dawn of a new century has ushered in an exciting and unprecedented opportunity to understand the functioning of the human body and mind. Along with rapid advancements in all medical arenas, the issue of women’s health has risen to prominence during the past two decades.
Women’s health and the diseases and disorders that affect women’s health have been widely recognized. Women’s health is a reflection of the overall quality of life in the United States and directly affects all other aspects of health, including men’s health and children’s health. There is now widespread recognition that the medical community, including researchers and clinicians, must understand how differences in sex and gender as well as cultural, ethnic and socioeconomic backgrounds influence the causes, diagnoses, progression and treatment of diseases.
Therapeutics and Diagnostics for Women's Disorders( BIO043D )
Publish Date: Mar 2009
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
Therapeutics and Diagnostics for Women's Disorders
Customize This Report More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum